Recent resignation of FDA Commissioner Marty Makary in May 2026 elevated Kyle Diamantas to acting commissioner while the Trump administration conducts a search for a permanent nominee, with names including Sara Brenner, Grace Graham, Brett Giroir, and Stephen Hahn under consideration. Senate confirmation requirements, preferences for candidates with MD or PhD credentials, and focus on policy priorities such as drug approvals and food regulation have created a competitive field among internal agency figures and prior officials. This process, combined with the approaching midterm elections, sustains tight trader pricing between leading contenders and the substantial probability of no formal announcement by year-end.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于Kyle Diamantas 29%
Brett Giroir 10.0%
Stephen Hahn 8%
Grace Graham 7.7%
$11,311 交易量
$11,311 交易量
2026-12-31
Kyle Diamantas
29%
Stephen Hahn
8%
Brett Giroir
15%
Grace Graham
8%
Sara Brenner
31%
No announcement by December 31
43%
Kyle Diamantas 29%
Brett Giroir 10.0%
Stephen Hahn 8%
Grace Graham 7.7%
$11,311 交易量
$11,311 交易量
2026-12-31
Kyle Diamantas
$1,636 交易量
29%
Stephen Hahn
$1,461 交易量
8%
Brett Giroir
$2,265 交易量
15%
Grace Graham
$3,407 交易量
8%
Sara Brenner
$1,992 交易量
31%
No announcement by December 31
$550 交易量
43%
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary in May 2026 elevated Kyle Diamantas to acting commissioner while the Trump administration conducts a search for a permanent nominee, with names including Sara Brenner, Grace Graham, Brett Giroir, and Stephen Hahn under consideration. Senate confirmation requirements, preferences for candidates with MD or PhD credentials, and focus on policy priorities such as drug approvals and food regulation have created a competitive field among internal agency figures and prior officials. This process, combined with the approaching midterm elections, sustains tight trader pricing between leading contenders and the substantial probability of no formal announcement by year-end.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
市场开放时间： May 12, 2026, 7:59 PM ET
交易量
$11,311结束日期
2026-12-31市场开放时间
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.Recent resignation of FDA Commissioner Marty Makary in May 2026 elevated Kyle Diamantas to acting commissioner while the Trump administration conducts a search for a permanent nominee, with names including Sara Brenner, Grace Graham, Brett Giroir, and Stephen Hahn under consideration. Senate confirmation requirements, preferences for candidates with MD or PhD credentials, and focus on policy priorities such as drug approvals and food regulation have created a competitive field among internal agency figures and prior officials. This process, combined with the approaching midterm elections, sustains tight trader pricing between leading contenders and the substantial probability of no formal announcement by year-end.
This market will resolve according to the first individual Donald Trump announces as his pick to be United States Food and Drug Administration (FDA) Commissioner.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
An announcement from Donald Trump or the Trump administration stating their intent to nominate a specific individual to be United States Food and Drug Administration (FDA) Commissioner will suffice to resolve this market, regardless of whether a formal nomination actually occurs.
Qualifying announcements must explicitly present the relevant individual as the nominee or future nominee for FDA Commissioner.
Announcements of acting or interim appointments, or announcements which merely reveal potential candidates, will not qualify. Media reports, speculation, or other unofficial information will not qualify.
A formal presidential nomination of an individual to be United States Food and Drug Administration (FDA) Commissioner will also suffice to resolve this market. Formal nominations are defined as the submission of a nomination message to the U.S. Senate.
If Donald Trump does not announce his pick for the next United States Food and Drug Administration (FDA) Commissioner by December 31, 2026, 11:59 PM ET, this market will resolve to “No announcement by December 31”.
The resolution source for this market will be official information from Donald Trump and the Trump Administration; however, a consensus of credible reporting may also be used.
交易量
$11,311结束日期
2026-12-31市场开放时间
May 12, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent resignation of FDA Commissioner Marty Makary in May 2026 elevated Kyle Diamantas to acting commissioner while the Trump administration conducts a search for a permanent nominee, with names including Sara Brenner, Grace Graham, Brett Giroir, and Stephen Hahn under consideration. Senate confirmation requirements, preferences for candidates with MD or PhD credentials, and focus on policy priorities such as drug approvals and food regulation have created a competitive field among internal agency figures and prior officials. This process, combined with the approaching midterm elections, sustains tight trader pricing between leading contenders and the substantial probability of no formal announcement by year-end.
基于Polymarket数据的AI实验性摘要。这不是交易建议，也不影响该市场的结算方式。 · 更新于
警惕外部链接哦。
警惕外部链接哦。
常见问题